Dextech Medical Second Quarter 2025 Earnings: kr0.052 loss per share (vs kr0.058 loss in 2Q 2024)
Dextech Medical (NGM:DEX) Second Quarter 2025 Results
Key Financial Results
- Revenue: kr1.53m (up 75% from 2Q 2024).
- Net loss: kr961.0k (loss narrowed by 11% from 2Q 2024).
- kr0.052 loss per share (improved from kr0.058 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Dextech Medical shares are down 7.5% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 2 warning signs for Dextech Medical that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:DEX
Dextech Medical
Engages in the development of drug candidates with application in urological oncology, primarily prostate cancer.
Flawless balance sheet very low.
Market Insights
Community Narratives
